(Q100152354)

English

Phosphorylated heterodimers of ERBB2 KD mutants and EGFR, in complex with GRB2:GAB1, bind PI3K

An instance of the biological reaction in Homo sapiens with Reactome ID (R-HSA-9664933)

In more languages

default for all languages

No label defined

No description defined

edit

Statements

1 reference

8 July 2022

Signaling by ERBB2 KD Mutants

1 reference

8 July 2022

1 reference

8 July 2022

https://identifiers.org/reactome:R-HSA-9664933

1 reference

8 July 2022

p-6Y-ERBB2 KD mutants:EGF:p-6Y-EGFR:GRB2:GAB1 [plasma membrane]

quantity

1

object of statement has role

1 reference

8 July 2022

PIK3CA:PIK3R1 [cytosol]

quantity

1

object of statement has role

1 reference

8 July 2022

p-6Y-ERBB2 KD mutants:EGF:p-6Y-EGFR:GRB2:GAB1:PI3K [plasma membrane]

quantity

1

object of statement has role

1 reference

8 July 2022

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib

1 reference

8 July 2022

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

1 reference

8 July 2022

Combined blockade of activating mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer

1 reference

8 July 2022

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification

1 reference

8 July 2022

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations

1 reference

8 July 2022

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.

1 reference

8 July 2022

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

1 reference

8 July 2022

Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity

1 reference

8 July 2022

Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor

1 reference

8 July 2022

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

1 reference

8 July 2022

Identifiers

1 reference

8 July 2022

(Q100152354)

Phosphorylated heterodimers of ERBB2 KD mutants and EGFR, in complex with GRB2:GAB1, bind PI3K

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)